Gateway To China: Developing Biologics For The Fastest-Growing Patient Population On Earth

China is the world’s second-largest pharmaceutical market, following the US, with a market share around 12% in global pharmaceutical sales in 2021.* With an aging population and the rise of new indications, this population makes an attractive market for any biopharmaceutical company. In this webinar, hear from Yan Fang Ma, general manager of Thermo Fisher’s site in Hangzhou, China, as she describes the opportunities and challenges multinational companies may face bringing biologics and sterile drug products to market in China and the how the right CDMO partner can provide trusted guidance along the way.

*Mikulic, M. (2021, November 15). Pharmaceutical value share by country worldwide 2021. Statista. Retrieved November 8, 2022, from https://www.statista.com/statistics/1246593/value-share-of-pharmaceutical-companies-worldwide-by-country/ 

Key takeaways:

• What makes China an attractive market for biopharmaceutical companies?
• What challenges do these companies face to develop and manufacture drugs in China?
• What factors to keep in mind when choosing a CDMO partner to enter the China market